Context Therapeutics Inc. Contracts & Agreements
45 Contracts & Agreements
- Business Finance (14 contracts)
- Business Operations (11)
- Human Resources (11)
- Intellectual Property (3)
- Uncategorized (6)
- LICENSE AGREEMENT (Filed With SEC on September 23, 2024)
- Form of Stock (Filed With SEC on August 7, 2024)
- Form of Stock Option Agreement (Inducement Grant) of Context Therapeutics Inc (Filed With SEC on August 7, 2024)
- Employment Agreement, dated August 1, 2024, between (Filed With SEC on August 7, 2024)
- ASSET PURCHASE AGREEMENT (Filed With SEC on July 10, 2024)
- Registration Rights Agreement (Filed With SEC on May 2, 2024)
- Securities Purchase Agreement, dated May 1, 2024, by and between the Company and the Purchasers named therein (Filed With SEC on May 2, 2024)
- PRE-FUNDED COMMON STOCK PURCHASE WARRANT CONTEXT THERAPEUTICS INC. (Filed With SEC on May 2, 2024)
- Description of Securities of Context Therapeutics Inc (Filed With SEC on March 21, 2024)
- Amendment No (Filed With SEC on March 6, 2024)
- Termination Agreement of the Clinical Trial Collaboration and Supply Agreement, dated March 21, 2023 between Context Therapeutics Inc. and Berlin-Chemie AG - Menarini Group (Filed With SEC on March 22, 2023)
- Description of Securities of Context Therapeutics Inc (Filed With SEC on March 22, 2023)
- Amendment No. 1 (Filed With SEC on March 22, 2023)
- License Agreement, dated November (Filed With SEC on November 9, 2022)
- Development and Manufacturing Services Agreement, dated November (Filed With SEC on November 9, 2022)
- Amendment No. 3 to Process Development Agreement (Filed With SEC on November 9, 2022)
- Clinical Trial Collaboration and Supply Agreement, dated August 1, 2022, by and between Context Therapeutics Inc. and Berlin-Chemie AG - Menarini Group (Filed With SEC on August 11, 2022)
- Amendment No. 2 to Consulting Agreement, dated June 17, 2022, between OncoStrategy, LLC and Context Therapeutics Inc (Filed With SEC on August 11, 2022)
- Form of Common Stock Purchase Warrant (Filed With SEC on May 11, 2022)
- Amendment No. 1 to Consulting Agreement, dated March (Filed With SEC on March 23, 2022)
- Employment Agreement (Filed With SEC on March 23, 2022)
- Securities Purchase Agreement, dated December 1, 2021, by and between Context Therapeutics Inc. and the purchasers named therein (Filed With SEC on December 2, 2021)
- Registration Rights Agreement, dated December 1, 2021, by and between Context Therapeutics Inc. and the investors named therein (Filed With SEC on December 2, 2021)
- Form of Common Stock Purchase Warrant (Filed With SEC on December 2, 2021)
- Amended and Restated Employment Agreement, dated October 22, 2021, between Context Therapeutics Inc. and Martin Lehr (Filed With SEC on October 22, 2021)
- License Agreement, dated August 23, 2021, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (Filed With SEC on September 13, 2021)
- Form of Underwriting Agreement (Filed With SEC on July 2, 2021)
- Form of Indemnification Agreement between Context Therapeutics Inc. and its officers and directors (Filed With SEC on June 16, 2021)
- Amendment No. 2 to Process Development Agreement, dated June 3, 2021, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (Filed With SEC on June 16, 2021)
- Investors Rights Agreement, dated December 22, 2020, among Context Therapeutics LLC and certain investors (Filed With SEC on May 27, 2021)
- Form of Stock Certificate of Common Stock (Filed With SEC on May 27, 2021)
- Right of First Refusal and Co-Sale Agreement, dated December 22, 2020, among Context Therapeutics LLC and certain investors (Filed With SEC on May 27, 2021)
- Voting Agreement, dated December 22, 2020, among Context Therapeutics LLC and certain investors (Filed With SEC on May 27, 2021)
- Research Collaboration and License Agreement, dated April 6, 2021, between Context Therapeutics LLC and Integral Molecular, Inc (Filed With SEC on May 27, 2021)
- Process Development Agreement, dated March 6, 2020, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (Filed With SEC on May 27, 2021)
- Amendment No. 1 to Process Development Agreement, dated April 21, 2021, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (Filed With SEC on May 27, 2021)
- Asset Purchase Agreement, dated as of December 15, 2017, between Context Biopharma Inc. and Arno Therapeutics, Inc (Filed With SEC on May 27, 2021)
- Context Therapeutics LLC 2015 Option Plan (Filed With SEC on May 27, 2021)
- Context Therapeutics Inc. 2021 Long-Term Incentive Plan (Filed With SEC on May 27, 2021)
- Form of Stock Option Agreement under the Context Therapeutics Inc. 2021 Incentive Award Plan (Filed With SEC on May 27, 2021)
- Form of Stock Grant Agreement under the Context Therapeutics Inc. 2021 Long-Term Incentive Plan (Filed With SEC on May 27, 2021)
- Consulting Agreement, dated October 23, 2019, between William Rencher and Context Therapeutics LLC (Filed With SEC on May 27, 2021)
- Consulting Agreement, dated February 25, 2021, between Evan Dick and Context Therapeutics LLC (Filed With SEC on May 27, 2021)
- Consulting Agreement, dated May 7, 2021, between OncoStrategy, LLC and Context Therapeutics Inc (Filed With SEC on May 27, 2021)
- Form of Director Services Agreement (Filed With SEC on May 27, 2021)
